More Percheron Therapeutics Limited news
Percheron Therapeutics LimitedASX: PER

Response to ASX Price and Volume Query

Oct 16, 2018 at 4:25 AM EDT · Issued by Percheron Therapeutics Limited

Filed with ASX · Oct 16, 2018 at 4:25 AM EDT · 5 pages · English

On 6ix: 6ix.com/news/response-to-asx-price-and-volume-query-344

Percheron Therapeutics Limited on 6ix

Story so far

  • Response to ASX Price & Volume QueryMay 14, 2018

Earlier from Percheron Therapeutics

  • Full Year Statutory AccountsAug 29, 2018
  • First Patient Dosed in Phase II DMD Clinical TrialAug 28, 2018
  • ANP initiates ATL1102 Phase II clinical trial in DMDJul 15, 2018
  • ATL1103/atesidorsen Early Access Program Progress UpdateJun 14, 2018
  • ATL1103 Phase II trial results published in leading journalMay 23, 2018

Later from Percheron Therapeutics

  • Pause in tradingMar 10, 2019
  • Placement to Accelerate Development of ATL1102 in DMDMar 12, 2019
  • Phase II clinical trial in DMD UpdateApr 3, 2019
  • Phase II clinical trial in DMD Fully EnrolledMay 23, 2019
  • Phase II DMD clinical trial on track for dosing completionJul 24, 2019
All Percheron Therapeutics news releases↗

Follow Percheron Therapeutics into a list and get an email when it puts out news.

Follow Percheron Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer